Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of an L- and T-Type Calcium Channel Blocker on 24-Hour Systolic Blood Pressure and Heart Rate in Hypertensive Patients

  • Komukai, Masae (Division of Cardiology, Showa University Fujigaoka Hospital) ;
  • Tsutsumi, Takeshi (Department of Ischemic Circulatory Physiology, University of Tokyo) ;
  • Ebado, Mio (Division of Cardiology, Showa University Fujigaoka Hospital) ;
  • Takeyama, Youichi (Division of Cardiology, Showa University Fujigaoka Rehabilitation Hospital)
  • Published : 2012.04.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: The aim of this study was to evaluate the effects of an L- and T-type calcium channel blocker (CCB) on 24- hour systolic blood pressure (24-hour SBP) and heart rate (24-hour HR) profiles in essential hypertensive patients. Subjects and Methods: Thirty-seven consecutive patients were enrolled in this study. The 24-hour SBP and HR were recorded before and after treatment with efonidipine (L- and T-type CCB, 40 mg), after waking. Changes in 24-hour SBP and HR and the diurnal to nocturnal SBP ratio were measured. The best-fit curves of changes in SBP and HR were depicted using a periodic function. Results: The mean 24-hour SBP and HR decreased significantly after treatment. The diurnal to nocturnal SBP ratio in dipper-type hypertension cases decreased from $16.7{\pm}6.1$% to $8.3{\pm}9.8$% (p<0.05), whereas in non-dipper hypertension cases, it increased from $2.3{\pm}2.9$% to $7.7{\pm}5.1$% (p<0.01). The antihypertensive effect was minimal at 5.0 hours after drug administration and it slowly recovered at a constant rate (2.1 mm Hg/h) over 12 hours in dipper cases. The median 24-hour changes in HR in the dipper and non-dipper cases were -2.3/ min and -5.4/min, respectively. A continuous reduction in the change in HR was seen from 3.5 to 23 hours after drug administration. Conclusion: The antihypertensive action of efonidipine was characterized by a slow recovery of the SBP decrease at a constant rate (2.1mm Hg/h) and a non-administration time dependent reduction in 24-hour HR.

Keywords

References

  1. Mancia G, de Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87. https://doi.org/10.1097/HJH.0b013e3281fc975a
  2. Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. $Ca^{2+}$ channel subtypes and pharmacology in the kidney. Circ Res 2007;100:342-53. https://doi.org/10.1161/01.RES.0000256155.31133.49
  3. Masumiya H, Shijuku T, Tanaka H, Shigenobu K. Inhibition of myocardial L- and T-type $Ca^{2+}$ currents by efonidipine: possible mechanism for its chronotropic effect. Eur J Pharmacol 1998;349:351-7. https://doi.org/10.1016/S0014-2999(98)00204-0
  4. Ge W, Ren J. Combined L-/T-type calcium channel blockers: ready for prime time. Hypertension 2009;53:592-4. https://doi.org/10.1161/HYPERTENSIONAHA.108.127548
  5. Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 2003;83:117-61. https://doi.org/10.1152/physrev.00018.2002
  6. Shin HS. T-type $Ca^{2+}$ channels and absence epilepsy. Cell Calcium 2006; 40:191-6. https://doi.org/10.1016/j.ceca.2006.04.023
  7. Ono K, Iijima T. Pathophysiological significance of T-type $Ca^{2+}$ channels: properties and functional roles of T-type $Ca^{2+}$ channels in cardiac pacemaking. J Pharmacol Sci 2005;99:197-204. https://doi.org/10.1254/jphs.FMJ05002X2
  8. Ishimitsu T, Kameda T, Akashiba A, et al. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007;30:621-6. https://doi.org/10.1291/hypres.30.621
  9. Kinoshita H, Kuwahara K, Takano M, et al. T-type $Ca^{2+}$ channel blockade prevents sudden death in mice with heart failure. Circulation 2009;120:745-52.
  10. Hermida RC, Ayala DE, Portaluppi F. Circadian variation of blood pressure: the basis for the chronotherapy of hypertension. Adv Drug Deliv Rev 2007;59:904-22. https://doi.org/10.1016/j.addr.2006.08.003
  11. Masuda Y, Takeguchi M, Arakawa C, et al. Antihypertensive and diuretic effects of NZ-105, a novel dihydropyridine derivative. Arch Int Pharmacodyn Ther 1990;304:247-64.
  12. Tanaka H, Shigenobu K. Efonidipine hydrochloride: a dual blocker of L- and T-type Ca2+ channels. Cardiovasc Drug Rev 2002;20:81-92.
  13. Tochikubo O, Ikeda A, Miyajima E, Ishii M. Effects of insufficient sleep on blood pressure monitored by a new multibiomedical recorder. Hypertension 1996;27:1318-24. https://doi.org/10.1161/01.HYP.27.6.1318
  14. Minami J, Ishimitsu T, Kawano Y, Numabe A, Matsuoka H. Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard. J Cardiovasc Pharmacol 1998;32:331-6. https://doi.org/10.1097/00005344-199808000-00023
  15. Hermida RC, Ayala DE, Chayan L, Mojon A, Fernandez JR. Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Chronobiol Int 2009;26:61-79. https://doi.org/10.1080/07420520802548135
  16. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003;107:1401-6. https://doi.org/10.1161/01.CIR.0000056521.67546.AA
  17. Ohtomo N, Kamo T, Watanabe M, Yoneyama K, Tanaka Y, Hayashi R. Power spectral densities of temporal variations of blood pressures. Jpn J Appi Phys 1996;35:5571-82. https://doi.org/10.1143/JJAP.35.5571
  18. Nakabeppu H, Asada M, Oda T, Shinozaki Y, Yajima T. Plasma and urinary metabolites of efonidipine hydrochloride in man. Xenobiotica 1996;26:229-39. https://doi.org/10.3109/00498259609046703
  19. Yamashita T, Masuda Y, Sakai T, Tanaka S, Kasuya Y. NZ-105, a new 1,4-dihydropyridine derivative: correlation between dihydropyridine receptor binding and inhibition of calcium uptake in rabbit aorta. Jpn J Pharmacol 1991;57:337-48. https://doi.org/10.1254/jjp.57.337
  20. Nold G, Herholz C, Sturm M, Hopf R, Lemmer B. Ambulatory blood pressure profiles in essential hypertensives after treatment with a new once daily nifedipine formulation. J Hum Hypertens 1999;13:173-7. https://doi.org/10.1038/sj.jhh.1000787
  21. White WB, Saunders E, Noveck RJ, Ferdinand K. Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. Am J Hypertens 2003;16:739-45. https://doi.org/10.1016/S0895-7061(03)00946-4
  22. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008;372:817-21. https://doi.org/10.1016/S0140-6736(08)61171-X
  23. Oh IY, Seo MK, Lee HY, et al. Beneficial effect of efonidipine, an L- and T-type dual calcium channel blocker, on heart rate and blood pressure in patients with mild-to-moderate essential hypertension. Korean Circ J 2010;40:514-9. https://doi.org/10.4070/kcj.2010.40.10.514
  24. Saito T, Fujii K, Takizawa T, et al. Effects of the new calcium antagonist efonidipine hydrochloride on resting and exercise hemodynamics in patients with stable effort angina. Arzneimittelforschung 1996;46:861-7.